PT-141 (Bremelanotide): Approved Medicine vs Research Lists (2026)

PT-141 (bremelanotide) is an approved medicine in some jurisdictions for specific indications; it also appears in research peptide marketplaces. Regulatory dosing and contraindications differ from informal "research protocol" lists.

Route matters

Approved use in many regions relies on a defined administration route and titration. Changing route or concentration without clinical oversight is not a neutral research tweak. For the related melanocortin peptide sold on grey markets, see Melanotan II - a different risk profile entirely.